# A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine

> **NCT05636319** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Suzhou Abogen Biosciences Co., Ltd.** · enrollment: 14168 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** ABO1020
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05636319
- **Lead sponsor:** Suzhou Abogen Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-23
- **Primary completion:** 2023-04-30
- **Final completion:** 2024-07-31
- **Target enrollment:** 14168 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05636319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05636319, "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05636319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*